Repligen Analyst Price Targets - Benzinga

Repligen Corp

RGENNASDAQ

Trade with Public

Trade with Public

$175.42

2.911.69%

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

© 2026 Benzinga | All Rights Reserved

Repligen Analyst Price Targets

Wall Street analyst price targets and consensus rating for Repligen (RGEN).

Price Target Range — 13 Quarters

Analyst Consensus — 18 Analysts

15Buy

3Hold

Consensus RatingBuy# Analysts18Avg. Consensus PT$177Upside to Avg. PT+1.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 7, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$175→$225
Sep 9, 2026	UBS	Dan Leonard	PT Raise	Buy	$195→$225
Jul 30, 2026	Wells Fargo	Evan Stampler	PT Raise	Overweight	$180→$185
Jul 29, 2026	JP Morgan	Casey Woodring	PT Raise	Overweight	$165→$175
Jul 7, 2026	Benchmark	Robert Wasserman	Upgrade	Hold→Buy	$185
Jul 6, 2026	Evercore ISI Group	Daniel Markowitz	PT Raise	Outperform	$150→$160
Jun 3, 2026	HSBC	Sidharth Sahoo	PT Cut	Buy	$170→$150
Jun 2, 2026	Wolfe Research	Mike Polark	Assumes	Outperform	$145
May 15, 2026	RBC Capital	Dan Leonard	Reinstates	Outperform	$160
May 6, 2026	JP Morgan	Casey Woodring	PT Cut	Overweight	$180→$165
May 6, 2026	Barclays	Luke Sergott	PT Raise	Overweight	$145→$160
Apr 20, 2026	Canaccord Genuity	Kyle Mikson	PT Cut	Hold	$165→$145
Apr 17, 2026	Roth Capital	Natalya Davies	Initiate	Buy	$160
Apr 14, 2026	Barclays	Luke Sergott	PT Cut	Overweight	$175→$145
Apr 6, 2026	Evercore ISI Group	Daniel Markowitz	PT Cut	Outperform	$170→$140
Mar 23, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$180→$208
Feb 25, 2026	UBS	Dan Leonard	PT Cut	Buy	$200→$195
Feb 25, 2026	Barclays	Luke Sergott	PT Cut	Overweight	$200→$175
Feb 25, 2026	Wells Fargo	Brandon Couillard	PT Cut	Overweight	$190→$180
Feb 25, 2026	Evercore ISI Group	Daniel Markowitz	PT Cut	Outperform	$180→$170

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Overweight on Repligen, Raises Price Target to $225

Barclays analyst Luke Sergott maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $175 to $225.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Repligen, Raises Price Target to $225

UBS analyst Dan Leonard maintains Repligen (NASDAQ:RGEN) with a Buy and raises the price target from $195 to $225.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Repligen, Raises Price Target to $185

Wells Fargo analyst Evan Stampler maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $180 to $185.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Repligen, Raises Price Target to $175

JP Morgan analyst Casey Woodring maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $165 to $175.

Benzinga Newsdesk

Repligen Strengthens Cell Therapy Portfolio With BioLife Acquisition

Repligen to acquire BioLife Solutions for $1.5B to boost cell therapy bioprocessing capabilities and expand global reach.

Vandana Singh

PRO
Benchmark Upgrades Repligen to Buy, Announces $185 Price Target

Benchmark analyst Robert Wasserman upgrades Repligen (NASDAQ:RGEN) from Hold to Buy and announces $185 price target.

Benzinga Newsdesk